Know Cancer

forgot password

A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia

Phase 1/Phase 2
18 Years
Open (Enrolling)
Refractory TdT-Positive Leukemia

Thank you

Trial Information

A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia

In the first phase the Study Objectives are to:

- Define the maximally tolerated dose (MTD) and recommended dose (RD) for administration
of cordycepin as a 1-hour IV infusion, administered 1 hour following administration of
an IV bolus of pentostatin, in subjects with refractory TdT-positive leukemia;

- Determine plasma ADA levels prior to pentostatin infusion and at 60 and 120 minutes
after administration of pentostatin;

- Determine the single and multiple dose pharmacokinetics (PK) of cordycepin given 1 hour
after a fixed dose of pentostatin;

- Assess cordycepin pharmacodynamics by measurement of blast cell apoptosis from
peripheral blood smears;

- Measure and quantitate any clinical responses in refractory TdT-positive leukemia
patients following cordycepin/pentostatin administration.

In the second phase, the Study Objectives are to assess the safety, PK, and clinical
outcomes of cordycepin in combination with pentostatin, at the RD, in a 20 subject cohort

Inclusion Criteria:

- TdT-positive leukemia (ALL, AML, or blastic CML) that has failed at least one
standard treatment regimen and for which no standard therapies are expected to result
in durable remission. Leukemia is minimally defined as at least 20% blast cells
present in marrow or peripheral blood. TdT must be expressed in at least 20% of
blast cells present and documented either immunologically or biochemically;

- Age ≥18 years;

- Must understand and voluntarily sign informed consent;

- Adequate non-hematologic organ system function, defined by:

- Creatinine ≤1.5 times the upper limit of normal (ULN) and/or creatinine
clearance ≥60 mL/min

- AST and/or ALT ≤2.5 times upper limit of normal (ULN)

- Total bilirubin within institutional normal range

- Normal EKG and LVEF >40%, measured by EKG and MUGA scan, radionuclide
ventriculogram, or echocardiogram

- Life expectancy >3 months;

- Performance status (PS) >70% Karnofsky or ECOG ≤2;

- Women of childbearing potential must have a negative serum pregnancy test within 7
days of starting study drug. A woman of child-bearing potential is a sexually mature
woman who has not undergone a hysterectomy or who has not been naturally
postmenopausal for at least 24 consecutive months (i.e., who has had menses at any
time in the preceding 24 consecutive months);

- Male or female of child-bearing potential must agree to use adequate contraceptive

Exclusion Criteria:

- Failure to meet inclusion criteria;

- Uncontrolled active infection;

- Extramedullary (CNS) disease;

- Serious concomitant medical illness, such as active infection, uncontrolled
congestive heart failure, or uncontrolled diabetes or other metabolic disorder, or
psychiatric illness;

- Pregnancy or lactation; females of child bearing potential must use adequate
contraceptive methods;

- Less than 3 weeks since prior chemotherapy, radiation therapy, or immunotherapy.
However, hydroxyurea is permitted up to 24 hours before the study is initiated;

- Less than 2 months following bone marrow or peripheral blood stem cell
transplantation or treatment with donor lymphocyte infusion (DLI).

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Establishment of the recommended dose (RD) of cordycepin, given one hour following a fixed dose of the ADA inhibitor pentostatin, in subjects with refractory TdT-positive leukemia

Outcome Time Frame:

one year

Safety Issue:


Principal Investigator

Swaminathan Padmanabhan, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cancer Therapy Research Center at UTHSCSA


United States: Food and Drug Administration

Study ID:




Start Date:

June 2008

Completion Date:

December 2010

Related Keywords:

  • Refractory TdT-Positive Leukemia
  • refractory TdT-positive leukemia
  • ALL
  • AML
  • blastic CML
  • Leukemia



Dana Farber Cancer Institute Boston, Massachusetts  02115
Brigham & Women's Hospital Boston, Massachusetts  02115
Cancer Therapy Reasearch Center at UTHSCA San Antonio, Texas  78229